Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations

21101 Background: Tumor angiogenesis and vascularization are essential for the growth and metastasis of tumors. VEGF-C expression and peritumoral lymphocyte density (PLD) are markers of angiogenesis. They have been correlated with poor prognosis in female breast cancer (FBC). The purpose of this study is to characterize VEGF-C expression and PLD in MBC and correlate with FBC specimens. Method: We reviewed records of patients diagnosed with MBC and FBC at the Cincinnati VAMC, from 1989 to 2006. Pathology slides were retrieved. We used VEGF-C (Host Rabbit, PAD: Z-CVC7) . Imunohistochemical stains of VEGF-C were given scores of 0 to 3+ based on nuclear stains. PLD was analyzed based on the number of lymphocyte cells surrounding the tumor; score of 0 to 3+. Slides were reviewed independently by two pathologists. Results: We found nine MBC cases and selected 9 FBC cases. Mean age was 72 in the male patients and 62 in the females. Stages of disease were distributed as follows in MBC versus FBC, 11% versus 22% stage 0, 23% versus 23% stage I, 44% versus 44% stage II, and 22% versus 11% stage IV. Ductal carcinoma was the predominant histology in 88% of FBC and 88% MBC. Other histological types included papillary (1 MBC) and lobular (1 FBC). Among the invasive MBC tumors , 75 % were ER+/PR +, 13% ER+/PR-, and 12% ER -/PR- , compared to 72 % ER+/PR+, 14% ER+/PR-, and 14% ER-/PR- in FBC. Eight out of the 9 MBC cases (89%) stained positive for VEGF-C expression, compared to one FBC case (11%). The 1 male breast intraductal carcinoma was positive for VEGF-C expression, compared to none of the two intraductal FBC. PLD was more intense in male than female tumors : score 0 or 1+: 44% in MBC versus 67% in FBC , score 2+: 22% in MBC Versus 22% in FBC, and score 3+: 22% in MBC versus 11% in FBC. VEGF-C expression did not seem to correlate with ER/PR status. The median survival for patients with MBC was 4.5 years and for patients with FBC 6.9 years. Conclusion: VEGF-C expression and PLD were more pronounced in MBC versus FBC. This finding may correlate with more aggressive behavior of breast tumor cells in male patients, more intense angiogenic reaction and lower median survival. Further studies are warranted to further elucidate the role of angiogenesis in male breast cancer and explore potential antiangiogenic therapeutic modalities. No significant financial relationships to disclose.

Download Full-text

Inmunophenotypic profiles of male breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.21180 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 21180-21180

Author(s):

T. Martin Gomez ◽

B. Torio ◽

I. Ruiz ◽

F. Arranz ◽

A. Arizcun

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

In Situ Hybridisation ◽

Case Series ◽

Response To Therapy ◽

Male Breast ◽

Breast Cancers ◽

Luminal A ◽

Luminal B ◽

Female Breast

21180 Background: Recently, inmunophenotypic characterization methods have allowed identification of female breast carcinomas into separate groups showing different behaviour and response to therapy: luminal A phenotype (RE +, HER2-neu - ), luminal B (RE +, HER2- neu + ), basal like (RE -, HER2-neu - ). In this study, we used immunohistochemistry to investigate the inmunophenotypic profile distribution of male breast cancer. Methods: all the male breast cancers were obtained from the files of the Departments of Pathology of Hospital Río Carrión in Palencia, Spain, since 1996. A total of 9 cases were reviewed to confirm the diagnosis and to characterize each tumour. The following CK immunohistochemistry was performed: 8/18 and 5 (Dako, Carpinteria, CA, USA) in a Dako autostainer. ER was interpreted as positive if > 10% of the cells were staining. Normal skin and tonsils were used as positive controls for the CK and a known breast cancer for the ER immunohistochemistry. Results: five cases expressed RE and were HER2-neu negative, so they have a luminal-A phenotype. The four cases that expressed the luminal-B pehnotype expressed RE and HER2-neu; we demonstrated gene amplification of the HER-neu gene using fluorescent in situ hybridisation (FISH) in those cases. Respect the CKs profile, all cases were positive for CK 8/18 and negative with CK 5, vimentin and p63, characteristic of luminal-like CK expression profile, according wiht the literature. Conclusions: this is the first case series of male breast cancer patients that provides inmunophenotypic profile data on this rare disease in only one center in Spain. We comunicate that the vast majority of these tumours express the phenotype of luminal-like CKs. None of our patients were basal-like tumours. The percentage expression of Her-2 parallels the finding in female breast cancers and this should be analysed for its predictive significance, according to new specific biological treatments. No significant financial relationships to disclose.

Download Full-text

Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2009.23.8162 ◽

2010 ◽

Vol 28 (2) ◽

pp. 232-239 ◽

Cited By ~ 213

Author(s):

William F. Anderson ◽

Ismail Jatoi ◽

Julia Tse ◽

Philip S. Rosenberg

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Breast Cancer Incidence ◽

Female Breast Cancer ◽

Male Breast ◽

Breast Cancers ◽

Men And Women ◽

Female Breast ◽

Estrogen Receptor Positive ◽

Over Time

Purpose Because of its rarity, male breast cancer is often compared with female breast cancer. Patients and Methods To compare and contrast male and female breast cancers, we obtained case and population data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program for breast cancers diagnosed from 1973 through 2005. Standard descriptive epidemiology was supplemented with age-period-cohort models and breast cancer survival analyses. Results Of all breast cancers, men with breast cancer make up less than 1%. Male compared with female breast cancers occurred later in life with higher stage, lower grade, and more estrogen receptor–positive tumors. Recent breast cancer incidence and mortality rates declined over time for men and women, but these trends were greater for women than for men. Comparing patients diagnosed from 1996 through 2005 versus 1976 through 1985, and adjusting for age, stage, and grade, cause-specific hazard rates for breast cancer death declined by 28% among men (P = .03) and by 42% among women (P ≈ 0). Conclusion There were three intriguing results. Age-specific incidence patterns showed that the biology of male breast cancer resembled that of late-onset female breast cancer. Similar breast cancer incidence trends among men and women suggested that there are common breast cancer risk factors that affect both sexes, especially estrogen receptor–positive breast cancer. Finally, breast cancer mortality and survival rates have improved significantly over time for both male and female breast cancer, but progress for men has lagged behind that for women.

Download Full-text

Male Breast Cancer: Reevaluate Our Opinion

Case Reports in Oncological Medicine ◽

10.1155/2020/6245415 ◽

2020 ◽

Vol 2020 ◽

pp. 1-3

Author(s):

Santosh Kale ◽

Rajmohan Rammohan ◽

Vilma Vas ◽

Chris Elsayad

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Hormonal Therapy ◽

Female Breast Cancer ◽

Breast Cancer Treatment ◽

Male Breast ◽

Breast Cancers ◽

Treatment Protocols ◽

Female Breast ◽

Cancer Treatment Protocols

Male breast cancers (MBCs) are relatively uncommon malignancy with less than 1% incidence. MBC presents at a later age with a more advanced presentation as compared to the female breast cancer. Due to the paucity of the number of cases and trials regarding the MBC, female breast cancer treatment protocols are applied. Mastectomy and hormonal therapy remains the mainstay of treatment. Moreover, the data about prognosis of MBC remains limited.

Download Full-text

Male Versus Female Breast Cancers

Archives of Pathology & Laboratory Medicine ◽

10.5858/2003-127-36-mvfb ◽

2003 ◽

Vol 127 (1) ◽

pp. 36-41 ◽

Cited By ~ 3

Author(s):

D. Muir ◽

R. Kanthan ◽

S. C. Kanthan

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Progesterone Receptor ◽

Male Breast Cancer ◽

Male Breast ◽

High Grade ◽

Breast Cancers ◽

Receptor Status ◽

Female Breast ◽

Grade 3

Abstract Context.—The rate of male breast cancer is a small fraction of that observed in females, thus severely limiting our understanding of the pathogenesis of this condition. It remains unclear whether the biological behavior and tumor progression associated with male breast cancer parallel that of the female form. Objectives.—To evaluate the immunohistochemical profile of male breast carcinomas and to compare this profile with that of stage-matched female breast cancers. Design.—Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Foundation over a period of 26 years (1970–1996). Fifty-nine of these cases had formalin-fixed, paraffin-embedded tissue blocks available for the purposes of this study. All cases were reviewed and a standardized modified Bloom-Richardson grading criterion was applied. Estrogen receptor status, progesterone receptor status, c-Erb-B2 expression, p53 expression, and Bcl-2 expression were evaluated by immunohistochemistry. Results from 240 consecutive cases of stage-matched female breast cancers analyzed in the same laboratory were used as a standard set for comparison. Results.—Male breast cancers tended to be high grade (85% grade 3) in comparison with the female breast cancers (50% grade 3). In descriptive analysis across all stages of disease, male carcinomas were more frequently estrogen receptor positive (81% vs 69%) than their female counterparts. Despite their high grade, they were less likely to overexpress p53 (9% vs 28%) and Erb-B2 (5% vs 17%) than the female counterparts. There was no significant difference in either progesterone receptor (63% vs 56%) or Bcl-2 (79% vs 76%) overexpression. Stratified analysis by stage-matched controls showed no statistically significant differences among the men and women with stage I disease. However, in stage II–matched samples, statistically significant differences were observed between the 2 groups. The male cancers were more likely to overexpress estrogen receptor (81.6% vs 64.4%, P = .04), progesterone receptor (71.1% vs 47.5%, P = .01), and Bcl-2 (78.9% vs 69.4%, P = .20). They also showed statistically significant lower expression of p53 (7.9% vs 36.3%, P = .001) and Erb-B2 (5.3% vs 23.8% P = .01). Conclusion.—Male breast cancers display distinct immunophenotypic differences from those occurring in women, implying a different pathogenesis in the evolution and progression of this disease. Such differences may play key roles in therapeutic management, warranting different treatment strategies in comparison to female breast cancers.

Download Full-text

Assessment of Knowledge and Attitude Regarding Female and Male Breast Cancer among Adults of South India

Global Journal of Medical Research ◽

10.34257/ljmhrvol21is3pg13 ◽

2021 ◽

pp. 13-20

Author(s):

Anwitha Johns ◽

Satish Kumar B P ◽

Lavanya P R

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Female Breast Cancer ◽

Incidence Rates ◽

Male Breast ◽

Basic Knowledge ◽

Nominal Data ◽

Female Breast ◽

South Indian ◽

Knowledge And Attitude

Background & Objectives: Breast cancer is the second leading reason for cancer death in women. Incidence rates of male breast cancer have increased by 0.2- 1% per year. The lack of knowledge and awareness of male breast cancer leads to its detection at a late stage in men. This study is to assess the knowledge and attitude of south Indian adults towards male and female breast cancer. Methods: To assess the knowledge and attitude of adults on breast cancer, a questionnaire regarding basic knowledge and attitudes was formulated using Google forms. Numbers and percentages were formed to review categorical and nominal data. Chi-square (χ2) test was used for the comparison between the awareness of female breast cancer and male breast cancer. P < 0.05 was set as the level of significance.

Download Full-text

Male breast cancer: Medical and psychological management in comparison to female breast cancer. A review

Cancer Treatment Communications ◽

10.1016/j.ctrc.2016.03.004 ◽

2016 ◽

Vol 7 ◽

pp. 23-34 ◽

Cited By ~ 6

Author(s):

Tricia L. da Silva

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Female Breast Cancer ◽

Male Breast ◽

Female Breast ◽

Psychological Management

Download Full-text

Male Breast Cancer: A Population-Based Comparison with Female Breast Cancer.

10.1158/0008-5472.sabcs-09-2075 ◽

2009 ◽

Cited By ~ 1

Author(s):

W. Anderson ◽

I. Jatoi ◽

P. Rosenberg

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Population Based ◽

Female Breast Cancer ◽

Male Breast ◽

Female Breast

Download Full-text

Is Male Breast Cancer Similar or Different than Female Breast Cancer?

Breast Cancer Research and Treatment ◽

10.1023/b:brea.0000010701.08825.2d ◽

2004 ◽

Vol 83 (1) ◽

pp. 77-86 ◽

Cited By ~ 171

Author(s):

William F. Anderson ◽

Michelle D. Althuis ◽

Louise A. Brinton ◽

Susan S. Devesa

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Female Breast Cancer ◽

Male Breast ◽

Female Breast

Download Full-text

Male breast cancer: Prognostic factors evaluation in a 35-year service

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e11618 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e11618-e11618

Author(s):

R. D. Botan ◽

M. N. Alvares ◽

A. Hassan

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Prognostic Factors ◽

Male Breast Cancer ◽

Survival Curve ◽

Local Treatment ◽

Female Breast Cancer ◽

Male Breast ◽

Breast Cancer Patients ◽

Female Breast

e11618 Background: Treatment for male breast cancer is based on the results of large clinical trials for female breast cancer. Although peculiar differences do exist between men and women, very little is known about the prognostic factors in male breast cancer, even though female breast cancer practical conducts are widely used in male breast cancer. The rarity of this condition makes very difficult to produce randomized trials. Methods: This study is populational and epidemiological and evaluated male breast cancer patients from January 1974 to December 2001 about its prognostic characteristics. Data were collected retrospectively and the sample has been described using descriptive statistics methods. Survival curve was built using Kaplan-Meier method. Staging system was standardized as in the sixth edition of American Joint Committee on Cancer, independently on when the diagnose was made. Due to differences throughtout 35 years on therapeutic on breast cancer, treatment options were categorized in groups to make the survival evaluation possible. Results: From 45 patients with male breast cancer, 91% presented ductal histology, 26% were negative axillary, 9.1% were T1, 25% were T2, 4.5% were T3, 50% were T4 and 12.12% presented with distant metastasis at diagnose. Seventy nine percent were submitted to radical local treatment, while 34% had not been submitted to any kind of systemic treatment (neoadjuvant, adjuvant e hormone therapy). Forty percent of patients have not presented distant recurrence, while 58.3% have not presented local recurrence. A median survival of 126 months has been observed to the analyzed population, ranging from 69–182 months. Five-year survival was 72% and 10-year survival was 54%. These data agreed with the available data in the published literature. Conclusions: Male breast cancer appears to behave biologically and clinically very similar to female breast cancer, but differences do exist and need to be elucidated. Randomized multi-center clinical trials become necessary, as systematic reviews, to build higher statistic power studies. No significant financial relationships to disclose.

Download Full-text